Reuters logo
BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
2017年11月10日 / 下午4点14分 / 10 天前

BRIEF-MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS

Nov 10 (Reuters) - Mesoblast Ltd:

* MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS

* ‍INFUSIONS WERE WELL-TOLERATED AND THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED DURING 52-WEEK PERIOD IN TRIAL​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below